ASLAN Pharmaceuticals Limited (ASLN): Price and Financial Metrics

ASLAN Pharmaceuticals Limited (ASLN): $0.50

0.01 (+2.03%)

POWR Rating

Component Grades













Add ASLN to Watchlist
Sign Up

Industry: Biotech



in industry

ASLN Stock Price Chart Interactive Chart >

Price chart for ASLN

ASLN Price/Volume Stats

Current price $0.50 52-week high $3.81
Prev. close $0.49 52-week low $0.36
Day low $0.50 Volume 99,900
Day high $0.52 Avg. volume 223,039
50-day MA $0.50 Dividend yield N/A
200-day MA $1.12 Market Cap 35.01M

ASLAN Pharmaceuticals Limited (ASLN) Company Bio

ASLAN Pharmaceuticals Pte. Ltd., a biotechnology company, develops immuno-oncology agents and targeted therapies. It offers ASLAN001, a pan-HER inhibitor for solid tumours; and ASLAN002, a cMET inhibitor for solid tumours. The company also inlicenses preclinical and early clinical/development compounds and candidate drugs from pharmaceutical companies focusing on oncology, respiratory, and inflammation diseases; gets proof of concept (PoC) for the partnered compounds in Asia; and outlicenses PoC compounds back to partner for development and launch. It sells its products in Asia and internationally. ASLAN Pharmaceuticals Pte. Ltd. was founded in 2010 and is based in Singapore.

ASLN Latest News Stream

Event/Time News Detail
Loading, please wait...

ASLN Latest Social Stream

Loading social stream, please wait...

View Full ASLN Social Stream

Latest ASLN News From Around the Web

Below are the latest news stories about ASLAN Pharmaceuticals Ltd that investors may wish to consider to help them evaluate ASLN as an investment opportunity.

Analysts Offer Insights on Healthcare Companies: BioDelivery (BDSI), Aslan Pharmaceuticals (ASLN) and Compass Therapeutics (CMPX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioDelivery (BDSI – Research Report), Aslan Pharmaceuticals (ASLN – Research Report) and Compass Therapeutics (CMPX – Research Report). BioDelivery (BDSI) H.C. Wainwright analyst Oren Livnat maintained a Hold rating on BioDelivery today and set a price target of $4.50. The company's shares closed last Thursday at $3.18. According to TipRanks.

Christine Brown on TipRanks | January 21, 2022

ASLAN (ASLN) Starts Phase IIb Study in Atopic Dermatitis

ASLAN (ASLN) screens the first patient in the phase II dose ranging study evaluating its investigational monoclonal antibody in patients with atopic dermatitis.

Yahoo | January 21, 2022

Aslan Pharmaceuticals begins phase2b study of ASLAN004 for eczema

Aslan Pharmaceuticals (ASLN) screened the first patient in its phase 2b dose-ranging study of eblasakimab in adults with moderate-to-severe atopic dermatitis ((AD)), also

Seeking Alpha | January 20, 2022

ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic Dermatitis

The TRials with EblasaKimab in Atopic Dermatitis (TREK-AD) study will evaluate the efficacy and safety of ASLAN004, now known as eblasakimab, a potential first-in-class antibody targeting the IL-13 receptorThis dose-ranging study is expected to enroll approximately 300 patients and will evaluate 4 dose regimensTopline results are expected in 1H 2023 MENLO PARK, Calif. and SINGAPORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused bioph

Yahoo | January 20, 2022

ASLAN Pharmaceuticals to Host New Episode in A4 KOL Series: Aspects of Atopic Dermatitis and ASLAN004

- Management to host the second webinar in ASLAN’s A4 series on Thursday, January 20, 2022, at 12:00pm ET MENLO PARK, Calif., and SINGAPORE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will host the second episode in its series of Key Opinion Leader (KOL) events on the emerging Atopic Dermatitis (AD) landscape and

Yahoo | January 18, 2022

Read More 'ASLN' Stories Here

ASLN Price Returns

1-mo 23.76%
3-mo -44.44%
6-mo -55.36%
1-year -84.85%
3-year -85.03%
5-year N/A
YTD -55.36%
2021 -38.80%
2020 -9.85%
2019 -43.61%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5432 seconds.